In preclinical studies, DT-818 has demonstrated a potential best-in-disease profile for DM1, including a greater than 90% reduction in toxic RNA foci in DM1 patient cells, corresponding splicing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback